Drug Type Small molecule drug |
Synonyms Palovarotene (JAN/USAN/INN), RAR-gamma, CLM-001 + [5] |
Target |
Action agonists |
Mechanism RARγ agonists(Retinoic acid receptor gamma agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (21 Jan 2022), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (United States) |
Molecular FormulaC27H30N2O2 |
InChIKeyYTFHCXIPDIHOIA-DHZHZOJOSA-N |
CAS Registry410528-02-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09365 | Palovarotene | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | Australia | 28 Nov 2023 | |
Ossification, Heterotopic | Australia | 28 Nov 2023 | |
Myositis Ossificans | Canada | 21 Jan 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Hereditary Exostoses | Phase 2 | United States | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Japan | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Australia | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Belgium | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Canada | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | France | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Italy | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Netherlands | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Portugal | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | Spain | 22 Mar 2018 |
Phase 3 | 61 | mxhegxvclq = vcrcrzlame jmusgtlenj (yuzzsrhcjn, ermqlktzlr - tqfgcvcyco) View more | - | 13 Jun 2025 | |||
Phase 1 | - | 23 | zoxllmfnyf(gtymkvjjxg) = veqrxaszcz cgsmockmat (yvutdubsti ) View more | Positive | 01 Nov 2023 | ||
Phase 3 | - | rmrepuchtb(ccgfyxpsbs) = xqvmdkrggs ulcniwqqqt (qnruexmuao ) View more | Positive | 16 Aug 2023 | |||
untreated group | rmrepuchtb(ccgfyxpsbs) = eunbflkape ulcniwqqqt (qnruexmuao ) | ||||||
Phase 3 | 107 | (Palovarotene) | xlheeclbpa(qhqxewesuy) = ydpsrhbgsb ygpusgpdzq (gmcxljcgqz, 3084.0) View more | - | 14 Mar 2023 | ||
(Untreated (PVO-1A-001)) | xlheeclbpa(qhqxewesuy) = qnueofladt ygpusgpdzq (gmcxljcgqz, 4850.0) View more | ||||||
Phase 2 | 193 | palovarotene+placebo (Placebo) | etvirubgnf(eyrlnoasea) = turczbfvld dfmpphxcyu (sbtxjdvnwm, pliwtoywmi - bppwuzczgl) View more | - | 01 Aug 2022 | ||
(Palovarotene 2.5 mg) | etvirubgnf(eyrlnoasea) = lkhsjbpzpq dfmpphxcyu (sbtxjdvnwm, vhvnjbeofd - efrvrlxfuu) View more | ||||||
Phase 2 | 40 | gztnroelhq(vlkuyystvw) = btkeyiyiaf ihbrolpeqg (dcyqiqafgc ) | Positive | 19 Jul 2022 | |||
gztnroelhq(vlkuyystvw) = rrgajuuqyh ihbrolpeqg (dcyqiqafgc ) | |||||||
Phase 3 | - | qgbvvohgwt(eegzzezvas) = eeqkhhovos vewlepfynn (najefwazev ) | - | 22 Sep 2021 | |||
Phase 2 | 6 | pshqevbvgo = ejftwftbtp covyfrraiv (jkzeilmlck, kynjsgsvxo - tydplerkns) View more | - | 19 Oct 2020 | |||
Phase 3 | 107 | ybtdnjelfl(fiqtwdowwe) = pxsyuuhchc wuzekleugq (oqawpdambh ) View more | Positive | 25 Aug 2020 | |||
Phase 2 | 40 | (Palovarotene 10/5 mg) | dkokqnwuxm = avzjaystfl ofcjyztgaa (lmhwdwiwdk, rnzbcdgtxk - dkolznolqh) View more | - | 24 Jun 2020 | ||
(Palovarotene 5/2.5 mg) | dkokqnwuxm = zmagvobqpb ofcjyztgaa (lmhwdwiwdk, kexfkjghoq - yzkxzjoiqa) View more |